Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for AI upstart
→ A longtime researcher in cardiac regenerative medicine has closed a $26 million Series B to advance his development of iPSC-derived cardiomyocytes as a treatment for heart failure. Keiichi Fukuda convinced a number of new investors, including SBI Investment, JMDC, Gene Techno Science, Nissay Capital and SMBC Capital, to join Astellas Venture Management in backing Tokyo-based Heartseed. The biotech expects to launch its own Phase I/II for the lead drug in HFrEF late next year, while supporting another trial for dilated cardiomyopathy initiated by Keio University.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.